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Abstract Diagnosis and circumvention of multi-drug resistance
requires an understanding of the underlying cellular mechanisms.
In the model organism Saccharomyces cerevisiae, deletions of
PDR5 or ERG6 increase sensitivity to many small lipophilic
drugs. Pdr5p is a plasma membrane ATP-binding cassette
transporter that actively exports drugs, thereby lowering their
intracellular levels. The mechanism by which ERG6, an enzyme
in sterol biosynthesis, affects drug accumulation is less clear.
We show here that ERG6 limits the rate of passive drug
diffusion across the membrane, without affecting Pdr5p-
mediated drug export. Consistent with their action by distinct
mechanisms, PDR5 and ERG6 effects on drug accumulation are
additive. $ 2002 Published by Elsevier Science B.V. on behalf
of the Federation of European Biochemical Societies.
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1. Introduction
Multi-drug resistance is a common problem in the chemo-
therapeutic treatment of cancer and microorganism-caused
disease [1,2]. Among the several underlying causes, mecha-
nisms that a¡ect intracellular drug levels are prominent [1].
Increased activity of exporters with broad substrate speci¢city
leads to reduced intracellular accumulation and potency of
drugs [3^7]. Changes in the intracellular pH lead to reduced
drug sequestration [8]. Defects in transporter-mediated uptake
contribute to drug resistance in trypanosomes [9]. Finally,
changes in the lipid composition of the plasma membrane
have been suggested to a¡ect drug accumulation (reviewed
in [10]).
The non-pathogenic yeast Saccharomyces cerevisiae has
served as a model organism for the genetic identi¢cation of
multi-drug resistance mechanisms [4]. Wild-type yeast are nat-
urally resistant to many drugs that are toxic to higher eukary-
otes, suggesting that some resistance mechanisms are consti-
tutively active. One such mechanism is ATP-binding cassette
(ABC) transporter-mediated drug e¥ux. The yeast genome
encodes 22 putative ABC transporters. Four of these
(Pdr5p, Yor1p, Snq2p and Ycf1p), protect yeast from a
wide variety of drugs and confer increased resistance when
overexpressed (reviewed in [6]). Other loci contributing to
drug resistance include the transcriptional regulators Pdr1p,
Pdr3p, Yap1p and Sin4p, which control the expression of
ABC transporters or other resistance determinants [4,11]. Mu-
tations in proteins that a¡ect lipid metabolism suggest yet
another mechanism of drug resistance. Yeast lacking the
phosphatidylinositol transfer protein Sec14p homologues
Pdr16p and Pdr17p [12,13], or the C-24 sterol methyltransfer-
ase Erg6p, are hypersensitive to many drugs [14^21]. Muta-
tions in PDR16 and PDR17 lead to an increase in passive
drug uptake into cells [12]. The hypersensitivity of yeast lack-
ing Erg6p, an enzyme that acts in the late steps of ergosterol
biosynthesis, has been attributed to membrane ‘permeability’
changes that enable the uptake of small molecules [14,19].
Currently, it is unclear whether this is due to changes in pas-
sive di¡usion across the membrane or in active transport sys-
tems for these molecules. In support of the latter mechanism,
the ABC transporter Pdr5p has been reported to display re-
duced export activity in erg6v cells [21].
S. cerevisiae has also been a model system for genetic stud-
ies of mammalian steroid hormone signaling [22]. The small
lipophilic steroid hormones bind and activate intracellular re-
ceptors, which are hormone-dependent transcription factors.
Although steroid receptors are not naturally present in yeast,
this organism provides the basic machinery necessary for their
function [22]. Genetic screens in yeast have identi¢ed PDR5
and ERG6 as genes that inhibit the transcriptional response to
hormone, by preventing the intracellular accumulation of hor-
mone and subsequent receptor activation [23,24]. The ability
of Pdr5p to actively export steroids explains the increased
hormone accumulation in pdr5v cells [23,25,26]. The mecha-
nism by which defects in ERG6 increase intracellular hormone
levels is less clear.
In this study, we address the mechanism by which Erg6p
a¡ects sensitivity to steroids and other drugs. We show that
Pdr5p is functional in erg6v cells, that PDR5 and ERG6 have
additive e¡ects on drug resistance, and that Erg6p a¡ects
passive di¡usion of drugs across the membrane.
2. Materials and methods
2.1. Yeast strains
Strains used in this study are derived from YPH501 [27]. YNK310
(ERG6, PDR5, leu2: :GRE-lacZ), YNK410 (ERG6, pdr5: :GRE-lacZ,
leu2: :GRE-lacZ) [28], YNK589 (erg6: :HIS3, PDR5, leu2: :GRE-
lacZ) and YNK591 (erg6: :HIS3, pdr5: :GRE-lacZ, leu2: :GRE-lacZ)
carry integrated glucocorticoid-responsive LacZ reporters [28], as in-
dicated. ERG6 was disrupted with a polymerase chain reaction
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(PCR)-ampli¢ed erg6: :HIS3 fragment [24]. Gene integrations, disrup-
tions and segregations were con¢rmed by PCR analysis of genomic
DNA. Cells carried a TRP1, rat glucocorticoid receptor expression
plasmid (pRS314-GN795 or pG1-N795 in Fig. 1B) [23]. In addition,
YNK310 and YNK410 carried the HIS3 expression plasmid pRS313,
so as to have the same auxotrophic requirements as YNK589 and
YNK591 [27]. Cells were grown in standard rich media or synthetic
selective media (SD) lacking tryptophan and histidine.
2.2. L-Gal assays
Quantitative L-gal assays were carried out in 96-well microtitre
plates. Yeast grown overnight were diluted 1:20 in SD media contain-
ing hormone or carrier ethanol, grown for 16 h at 30‡C, permeabilised
with 5% (3-[(3-cholamidopropyl)dimethylammonio]-1-propane-sulfo-
nate) and assayed for L-gal activity [22].
2.3. Cycloheximide sensitivity
Cells grown overnight were diluted 1:15 in SD media containing 0,
1.5, 3, 6, 12, 25, 50, 100, 200, 400 or 800 ng/ml of cycloheximide, in
96-well microtitre plates. After growth for 16 h at 30‡C, cell density
was measured as A600.
2.4. Western analysis
Protein extracts from cells grown in SD media to an A600 of 0.7^0.9,
were resolved in sodium dodecyl sulphate^polyacrylamide gels, and
transferred to nitrocellulose membranes. Pdr5p and CPY were de-
tected with the corresponding rabbit polyclonal antibodies [29,30].
2.5. Rhodamine accumulation, uptake and e¥ux
To determine steady-state intracellular rhodamine 6G levels, expo-
nentially growing cells were incubated with 5 WM rhodamine 6G in
SD media for 1 h at 30‡C [28]. Cells were then analysed by £ow
cytometry using a FACScan (Becton Dickinson) and the Cellquest
software. Rhodamine e¥ux was determined as described by Kolacz-
kowski et al. [26] with minor modi¢cations. Exponentially growing
yeast (1.4U108) were washed, resuspended in 50 mM HEPES, pH 7,
5 mM 2-deoxy-D-glucose and 5 WM rhodamine 6G, and incubated
for 2 h at room temperature. De-energised, rhodamine-loaded cells
were washed once in 50 mM HEPES pH 7, and divided into two: one
part was resuspended in 5 ml 50 mM HEPES pH 7 (no energy) and
the other part in 5 ml of the same bu¡er containing 1 mM glucose
(+energy). After 15 min at 30‡C, cells were removed by centrifugation,
and the amount of rhodamine 6G released into the media was deter-
mined by £uorescence measurement using a Jasco FP-777 spectro£u-
orometer, an excitation wavelength of 529 nm (1.5 nm slit) and an
emission wavelength of 553 nm (3 nm slit). Measurements of rhod-
amine uptake were according to van den Hazel et al. [12]. Yeast
(1.4U108) grown at 30‡C in SD media (A600 of 0.4^0.6) were depleted
of energy by incubation at 30‡C for 2.5 h in energy-depletion bu¡er
(50 mM HEPES pH 7, 1 WM antimycin A, 5 mM 2-deoxy-D-glucose).
De-energised cells were collected, resuspended in 1 ml energy-deple-
tion bu¡er containing 5 WM rhodamine 6G, and incubated at 30‡C.
Aliquots taken at di¡erent times were washed, resuspended in 50 mM
HEPES pH 7, and subjected to £uorescence measurements as de-
scribed above. Cell £uorescence background, measured in parallel
incubations in the absence of rhodamine 6G, was subtracted from
£uorescence values in the presence of the drug.
3. Results
3.1. Pdr5p is active in erg6v cells
The drug hypersensitivity of erg6v cells could be due to a
decreased activity of membrane proteins that e¥ux the drugs
[21]. To evaluate the function of active drug-e¥ux systems, we
compared the activity of the endogenous yeast transporter
Pdr5p in erg6v to that in ERG6 cells. Pdr5p activity was
assessed by measuring its ability to regulate the intracellular
accumulation of three known Pdr5p substrates: dexametha-
sone (dex), cycloheximide, and rhodamine 6G, i.e. drugs with
distinct structures and cellular targets.
Dex binds and activates the intracellular glucocorticoid re-
ceptor, which is a ligand-regulated transcription factor. In
yeast that express the mammalian glucocorticoid receptor
and carry a glucocorticoid-inducible L-gal reporter, the intra-
cellular concentration of dex determines the percentage of
activated receptor molecules, and hence the production of
L-gal [22^24]. Pdr5p-mediated export decreases intracellular
dex levels, and thereby compromises L-gal induction [23]. A
comparison of Pdr5p activity in erg6v and ERG6 cells dem-
onstrated that the transporter was active in both strains
(Fig. 1). In erg6v cells, the presence of Pdr5p rendered cells
resistant to dex, shifting the dex concentration required to
induce half the maximal response (V2000 L-gal units) from
V1036 toV1034 M (compare erg6v,pdr5v to erg6v,PDR5 in
Fig. 1A). Pdr5p conferred a similar resistance to dex in ERG6
cells; comparable L-gal levels were induced by V2U1036 M
dex in ERG6,pdr5v and V1034 M dex in ERG6,PDR5 cells
(Fig. 1A). In conclusion, Pdr5p activity was independent of
ERG6 function.
ERG6 itself caused a shift in hormone responsiveness. Lack
of Erg6p increased sensitivity to dex by V10-fold in both
PDR5 and pdr5v cells (Fig. 1A). Importantly, the e¡ects of
PDR5 and ERG6 on hormone responsiveness were additive,
with the double erg6v,pdr5v yeast showing the highest sensi-
Fig. 1. Pdr5p confers resistance to dex in erg6v cells as e⁄ciently as
in ERG6 cells. Yeast strains YNK310 (ERG6,PDR5) (b), YNK410
(ERG6,pdr5v) (a), YNK589 (erg6v,PDR5) (R) and YNK591
(erg6v,pdr5v) (O) expressing the glucocorticoid receptor were
treated with the indicated dex concentrations for 16 h and assayed
for L-gal activity. The receptor was expressed from a low copy plas-
mid (pRS314-GN795) in all four strains (A), or from the low copy
plasmid in erg6v and a high copy plasmid (pG1-N795) in the ERG6
cells (B). The transcriptional activity of a hormone-independent glu-
cocorticoid receptor variant was not a¡ected by Pdr5p or Erg6p
[23,24]. Data are the mean and range of duplicates from three inde-
pendent experiments.
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tivity to dex. Because of the ERG6 e¡ect on hormone respon-
siveness, the regulatory e¡ect of Pdr5p was assessed over dif-
ferent dex concentrations in ERG6 and erg6v cells in the ex-
periment of Fig. 1A. To evaluate Pdr5p activity over similar
dex concentrations, we altered the assay conditions. We in-
creased the levels of glucocorticoid receptor expressed in the
ERG6 cells, using a high instead of low copy receptor expres-
sion plasmid. The increase in receptor levels led to the induc-
tion of L-gal at lower hormone concentrations (compare
ERG6 cells in Fig. 1B with the same cells in Fig. 1A). Under
these conditions, Pdr5p expression caused again comparable
shifts to the concentrations of dex required to induce L-gal in
erg6v and ERG6 cells, demonstrating clearly that Pdr5p is
similarly active in the two strains (Fig. 1B).
To determine the export e⁄ciency of Pdr5p for a second
substrate, we assessed the e¡ect of Pdr5p on cell growth in
increasing concentrations of the translation inhibitor cyclo-
heximide. A comparison of PDR5 to pdr5v cells showed
that Pdr5p conferred similar increases in resistance to the
drug in erg6v and ERG6 cells (Fig. 2). Thus, Pdr5p exports
cycloheximide e⁄ciently, independent of ERG6 function. As
with dex, yeast lacking both PDR5 and ERG6 showed the
highest sensitivity to cycloheximide, indicating that the e¡ects
of the two genes are additive.
The response to dex and the sensitivity to cycloheximide
re£ect indirectly the intracellular concentrations of the two
drugs. To measure Pdr5p activity on the accumulation of a
substrate directly, we determined the steady-state intracellular
levels of the £uorescent drug rhodamine 6G. Exponentially
Fig. 2. Pdr5p confers resistance to cycloheximide in both ERG6 and
ergv6 cells. Yeast strains YNK310 (ERG6,PDR5) (b), YNK410
(ERG6,pdr5v) (a), YNK589 (erg6v,PDR5) (R) and YNK591
(erg6v,pdr5v) (O) were grown in selective media containing the in-
dicated cycloheximide concentrations. The optical densities of the
cell cultures (A600) after 16 h of growth were plotted against the cy-
cloheximide concentration. Data are the average of duplicates from
at least three independent experiments.
Fig. 3. Pdr5p decreases the accumulation of rhodamine 6G in both
ERG6 and ergv6 cells. Yeast strains YNK310 (ERG6,PDR5),
YNK410 (ERG6,pdr5v), YNK589 (erg6v,PDR5) and YNK591
(erg6v,pdr5v) were incubated with 5 WM rhodamine 6G for 1 h.
Rhodamine 6G accumulation in cells was determined by £ow cy-
tometry. Data are from one experiment and are representative of
three independent experiments.
Fig. 4. Pdr5p-mediated e¥ux of rhodamine 6G is similar in ERG6
and erg6v cells. Yeast strains YNK310 (ERG6,PDR5), YNK410
(ERG6,pdr5v), YNK589 (erg6v,PDR5) and YNK591 (erg6v,pdr5v)
were depleted of energy and pre-loaded with rhodamine 6G for 2 h.
Rhodamine 6G released into the media during 15 min at 30‡C, in
the absence (dark bars) or presence (light bars) of energy (glucose),
was measured as described in Section 2. Data are the average from
two independent experiments.
Fig. 5. ERG6 and erg6v yeast express similar levels of Pdr5p. Pdr5p
was detected by Western analysis of protein extracts from duplicate
cultures of yeast strains YNK310 (ERG6,PDR5), YNK410
(ERG6,pdr5v), YNK589 (erg6v,PDR5) and YNK591 (erg6v,pdr5v),
using an anti-Pdr5p speci¢c antibody. An antibody against carboxy-
peptidase Y (CPY) was used to con¢rm comparable amounts of
protein load for extracts from the di¡erent strains.
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growing cells were incubated with rhodamine and analysed by
£ow cytometry. As shown in Fig. 3, the presence of Pdr5p
decreased rhodamine accumulation by about 10-fold in both
ERG6 and erg6v cells, demonstrating that Pdr5p is active in
erg6v yeast. As for the other substrates, ERG6 by itself caused
a signi¢cant decrease in the intracellular levels of rhodamine,
and the e¡ects of ERG6 and PDR5 were additive (Fig. 3).
To determine Pdr5p activity in a more direct manner, we
measured the energy-dependent Pdr5p-mediated e¥ux of
rhodamine 6G from intact cells. As seen in Fig. 4, Pdr5p
led to a similar increase in the amount of rhodamine released
into the medium from dye-pre-loaded ERG6 and erg6v cells
(164 and 194 £uorescence units/15 min, respectively, in the
presence of glucose). To exclude the possibility that a reduced
Pdr5p function could be compensated by higher expression
levels in erg6v cells, we checked Pdr5p levels by Western
analysis. Similar Pdr5p levels were seen in ERG6 and erg6v
cells, supporting the conclusion that ERG6 does not a¡ect
Pdr5p activity (Fig. 5).
3.2. ERG6 determines the rate of passive drug di¡usion
Our ¢ndings indicated that decreased drug e¥ux via Pdr5p
could not explain the increased accumulation of small lipo-
philic drugs in erg6v cells. We asked next whether ERG6
a¡ects the passive di¡usion of drugs across the plasma mem-
brane. For this, we measured the rate of uptake of rhodamine
6G in cells that were depleted of energy. The energy-depleted
state of the cells was con¢rmed by the lack of activity of the
ATP-dependent Pdr5p transporter (Fig. 4 and data not
shown). As seen in Fig. 6, rhodamine uptake was much faster
in erg6v than ERG6 energy-depleted cells, suggesting that
ERG6 function slows down the di¡usion of lipophilic drugs
across the membrane. Consistent with this, the rate of release
of rhodamine 6G from de-energised intact cells was also high-
er in erg6v than ERG6 cells (Fig. 4, compare rhodamine e¥ux
in erg6v and ERG6 cells in the absence of glucose.)
Changes in the rate of passive di¡usion can a¡ect the
steady-state intracellular levels of drugs only if the drugs are
actively maintained at a concentration gradient across the
membrane. Accordingly, ERG6 should have no e¡ect on the
steady-state rhodamine levels in energy-depleted cells. Indeed,
£ow cytometry measurements showed that de-energised ERG6
and erg6v cells accumulated the same high steady-state levels
of rhodamine 6G (data not shown), suggesting that lack of
ERG6 function and the ensuing increased di¡usion rate simply
enable drugs to attain a new equilibrium down their concen-
tration gradient.
4. Discussion
Several screens have identi¢ed erg6 mutants as yeast with
increased sensitivity to a broad range of chemical compounds
[19,20,24]. This hypersensitivity of erg6v cells has proved use-
ful in studies with small molecule inhibitors, such as Brefeldin
A, that are ine¡ective in wild-type yeast [16^18]. Still, the
mechanism by which ERG6 mutations allow increased drug
accumulation is not clear. At least two possibilities have been
suggested. First, deletion of ERG6 a¡ects drug uptake di-
rectly, by rendering the membrane bilayer permeable to small
molecules [14]. Second, deletion of ERG6 acts indirectly, by
compromising the activity of drug-e¥ux systems, such as
Pdr5p [21]. In this study, we demonstrate that deletion of
ERG6 increases the rate of passive drug di¡usion, thereby
increasing drug uptake directly and not via Pdr5p.
Several of our observations support a direct e¡ect of ERG6
on drug resistance. First, the e¡ects of ERG6 and PDR5 on
accumulation of drugs are additive. Notably, an erg6 mutant
has been isolated due to its increased sensitivity to the steroid
dex in a genetic screen that employed a pdr5v strain [24].
Second, Pdr5p activity is similar in erg6v and ERG6 cells,
as judged by its ability to confer resistance to dex and cyclo-
heximide, lower rhodamine accumulation, and mediate rhod-
amine e¥ux. A previous study suggesting reduced Pdr5p ac-
tivity in erg6v cells, has tested the activity of exogenously
expressed Pdr5p rather than of the endogenous genomically
expressed transporter; other erg6v defects, possibly in main-
taining high copy number plasmids or overexpressing Pdr5p,
may have led to the disparity in the results [21]. Finally, we
show that the rate of rhodamine uptake is faster in erg6v than
ERG6 energy-depleted cells devoid of Pdr5p and other energy-
dependent e¥ux activities. The faster passive di¡usion of a
drug across the membrane can lead to higher accumulation
in erg6v cells, if the drug is subject to mechanisms that main-
tain a lower intra- than extra-cellular concentration. In other
words, lack of Erg6p function facilitates di¡usion down a
concentration gradient. Interestingly, this implies that deletion
of ERG6 could lead to decreased intracellular accumulation of
di¡usible molecules that are actively concentrated inside the
cell.
Erg6p methylates the side chain of sterols, a modi¢cation
that is characteristic of membrane sterols of yeast, plants and
parasites but not of higher eukaryotes. As a result, erg6v
membranes contain predominantly zymosterol and cholesta-
5,7,24-trienol rather than ergosterol [14,15,30]. Though the
importance of sterols and lipids in determining membrane
properties has been recognised for a long time, the degree to
which ergosterol restricts the di¡usion of small lipophilic mol-
ecules in yeast is still surprising. Other lipid modifying activ-
ities seem to have similar e¡ects. Yeast lacking Pdr16p and
Pdr17p have altered membrane sterol and lipid composition,
display increased rates of passive drug di¡usion, and are hy-
persensitive to many drugs [12]. Thus, plasma membrane lipid
composition may be a useful target for novel antifungal drugs.
Fig. 6. Deletion of ERG6 leads to an increased rate of passive di¡u-
sion for rhodamine 6G. Yeast strains YNK410 (ERG6,pdr5v) (R)
and YNK591 (erg6v,pdr5v) (O) were depleted of energy and incu-
bated with 5 WM rhodamine 6G. Cell-associated £uorescence was
measured in aliquots taken at the indicated times after addition of
rhodamine, as described in Section 2. Data are the mean and range
of results from duplicate cultures in ¢ve independent experiments.
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Compounds that inhibit Erg6p, or possibly Pdr16p and
Pdr17p, could render pathogenic yeast more sensitive to al-
ready known and established drugs [2,31,32].
Multi-drug resistance in humans compromises the e⁄cacy
of chemotherapeutic regimens in the treatment of cancer. The
increased expression of ABC transporters such as P-glycopro-
tein and MRP is a well established cause of resistance [1,3,7].
However, additional mechanisms may contribute. For exam-
ple, plasma membrane ultrastructure can di¡er in multi-drug
resistant, compared to sensitive cells [33]. Changes in the
membrane sterol/phospholipid composition of resistant versus
sensitive mammalian cell lines have been reported (reviewed in
[10]). In many of these cases, it is still not clear whether or
how these changes contribute to resistance. It will be impor-
tant to establish whether membrane lipid composition con-
tributes to multi-drug resistance in mammals, as in yeast,
via mechanisms that are additive to the already known active
e¥ux systems.
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